Vera Therapeutics (VERA) Shares Outstanding (Diluted Average) (2021 - 2026)
Vera Therapeutics posted quarterly Shares Outstanding (Diluted Average) of $71.5 million for Q1 2026, up 12.26% year-on-year from $63.7 million in Q1 2025, and up 11.28% on a QoQ basis from $64.2 million in Q4 2025.
Vera Therapeutics (VERA) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $71.5 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 12.26% year-over-year to $71.5 million; the trailing twelve-month figure through Mar 2026 stood at $71.5 million (up 12.26% YoY), and the FY2025 full-year result was $64.2 million, up 16.1% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $71.5 million, up from $64.2 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $71.5 million in Q1 2026 and bottomed at $24.2 million in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $51.0 million (2024), against an average of $47.5 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) soared 369.07%; it then increased 12.26% in 2026.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $26.6 million in 2022, then soared by 60.73% to $42.7 million in 2023, then climbed by 29.55% to $55.3 million in 2024, then rose by 16.1% to $64.2 million in 2025, then grew by 11.28% to $71.5 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $71.5 million (Q1 2026), $64.2 million (Q4 2025), and $63.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Vera Therapeutics | 2.43 Bn | 1.83 Bn | - | 71.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71.48 Mn |
| Dec 31, 2025 | 64.23 Mn |
| Sep 30, 2025 | 63.85 Mn |
| Jun 30, 2025 | 63.73 Mn |
| Mar 31, 2025 | 63.67 Mn |
| Dec 31, 2024 | 55.33 Mn |
| Sep 30, 2024 | 53.54 Mn |
| Jun 30, 2024 | 52.85 Mn |
| Mar 31, 2024 | 50.97 Mn |
| Dec 31, 2023 | 42.71 Mn |
| Sep 30, 2023 | 42.12 Mn |
| Jun 30, 2023 | 40.99 Mn |
| Mar 31, 2023 | 37.67 Mn |
| Dec 31, 2022 | 26.57 Mn |
| Sep 30, 2022 | 27.22 Mn |
| Jun 30, 2022 | 25.66 Mn |
| Mar 31, 2022 | 24.23 Mn |
| Dec 31, 2021 | 13.44 Mn |
| Sep 30, 2021 | 10.79 Mn |
| Jun 30, 2021 | 5.47 Mn |